Current Challenges and Opportunities in Clinical Research Compliance

REFERENCES

1. ↵
   1. Clinical Trials Compliance

   (June 2003) FDA warning letter signals move to tighten oversight. Strategies for Medicare Billing, FDA, and Research Compliance, 2, 1–12.
2. ↵
   1. Office of the Inspector General

   (2003) Work Plan. Retrieved October 14, 2003 from the World Wide Web: http://oig.hhs.gov/publications/workplan.html.
3. ↵
   1. Federal Register

   (September 2003) Solicitation of Information and Recommendations for Developing Compliance Program Guidance for Recipients of NIH Research Grants. Retrieved October 14, 2003 from the World Wide Web: http://oig.hhs.gov/authorities/docs/FRcpgNIHsolicitation.pdf.
4. ↵
   1. Office of the Inspector General

   (CPG (2003)) Compliance Program Guidance for Pharmaceutical Manufacturers. Retrieved October 14, 2003 from the World Wide Web: http://oig.hhs.gov/fraud/docs/complianceguidance/042803pharmacymfgnonfr.pdf.
5. ↵
   1. Clinical Trials Compliance

   (September 2003) Sidestepping the five most common FDA compliance pitfalls, 2(9):1–3, Strategies for Medicare Billing, FDA, and Research Compliance.
6. ↵
   1. Gillis J.

   (June, 2002) A hospital's conflict of interest - Patients weren't told of stake in cancer drug. Retrieved October 14, 2003 from the World Wide Web: http://www.commondreams.org/headlines02/0630-03.htm.
7. ↵
   1. Haan H.

   (September, 2003) American Academy of Pharmaceutical Physicians. Retrieved October 14, 2003 from the World Wide Web: http://aapp.org/pdf/HansMayoPresentation.pdf.